Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder

(Source: PharmiWeb.com) The ENLIGHTEN clinical development program for ALKS 3831 comprises two key … For more information, please visit Alkermes’ website at www.alkermes.com.